Brief: Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity In Previously Treated Head And Neck Squamous Cell Carcinoma (Hnscc)

Merus NV

17/04/2023 15:32

Merus NV  MRUS.O :
    * MERUS’ PETOSEMTAMAB INTERIM DATA DEMONSTRATES CLINICALLY
MEANINGFUL ACTIVITY IN PREVIOUSLY TREATED HEAD AND NECK SQUAMOUS
CELL CARCINOMA (HNSCC)
    * MERUS NV - 37% OVERALL RESPONSE RATE (ORR) OBSERVED IN 43
EVALUABLE PATIENTS
    * MERUS NV - 6 MONTHS MEDIAN DURATION OF RESPONSE AS OF FEB.
1,
2023 DATA CUTOFF DATE

Source text for Eikon:  ID:nGNXtSctY 
Further company coverage:  MRUS.O